Kapynag Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.00 M
- Revenue Growth 689.55%
- Profit Growth 681.89%
- Ebitda -283.86%
- Net Worth 242.55%
- Total Assets 52.46%
About Kapynag Pharma
Kapynag Pharma Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 September 2017 (Seven years and five months 18 days old ). Its registered office is in Nashik, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹6.00 M.
Ashwini Dhondge, Lalit Dhondge, and Gangadhar Kakulate serve as directors at the Company.
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909MH2017PTC299496
- Company No.
299496
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Sep 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Kapynag Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lalit Dhondge  | Director | 21-Jan-2022 | Current |
| Ashwini Dhondge | Director | 05-Jan-2019 | Current |
| Gangadhar Kakulate | Director | 25-Jun-2022 | Current |
Financial Performance of Kapynag Pharma.
Kapynag Pharma Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 689.55% increase. The company also saw a substantial improvement in profitability, with a 681.89% increase in profit. The company's net worth Soared by an impressive increase of 242.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kapynag Pharma?
In 2021, Kapynag Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹6.00 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.60 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Mar 2022 | Hdfc Bank Limited | ₹6.00 M | Open |
How Many Employees Work at Kapynag Pharma?
Kapynag Pharma has a workforce of 15 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kapynag Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kapynag Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
